Comparative study of efficacy and safety of Omnic OCAS and doxazosin


如何引用文章

全文:

详细

It includes the results of the comparison study of efficiency and safety of Omnic Okas (tamsulosin) and doxazosin in the treatment of benign prostatic hyperplasia (BPH). The open 12-weeks trial included 62 patients with BPH. The positive results of Omnic Okas treatment were achieved in 96,7% of patients. The symptom index IPSS decreased on 53%, nocturia in 4,9 times, quality of life increased in 2,1 times, maximal urinary flow rate - on 55%, the residual urine decreased on 70%, adverse effects revealed in 3,3% patients. Positive effect was achieved in 71,9% and safety in 75,0%. Doxazosin have no advantages compared with Omnic Okas. The frequency of adverse effects was in 3,1-18,8%. Doxazosin decreased systolic and diastolic blood pressure on 19 and 9 hg mm, myocardial ischemia - in 15,6%, and arrhythmias - in 12,5% patients, positive orthostatic test was registered in 37,5% of patients. Omnic Okas was more effective and safe drug for treating symptoms of BPH.

作者简介

M Davidov

M Davidov

参考

  1. Лопаткин Н.А. Доброкачественная гиперплазия предстательной железы. М., 1999. 216 с.
  2. Урология по Дональду Смиту / Под ред. Э. Танахо, Дж. Маканинча. Пер. с англ. М., 2005. 819 с.
  3. Рациональная фармакотерапия в урологии / Под ред. Н.А. Лопаткина, Т.С. Перепановой. М., 2006. С. 258-290.
  4. Abrams P, Schulman CC, Vaage S, et al. Tamsulosin Study Group: Tamsulosin, a selective als-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction. Br J Urol 1995;76:325-26.
  5. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective a1A-adrenoceptor antagonist: a metaanalysis of two randomized, placebo-controlled multi-centre studies in patients with begign prostatic obstruction. Eur Urol 1996;29:155-67.
  6. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
  7. Лопаткин Н.А., Пытель Ю.А., Трапезникова М.Ф. и др. Омник (тамсулозин) в лечении больных с доброкачественной гиперплазией предстательной железы // Урология. 2001. № 1. С. 3-10.
  8. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patients quality of life. Urology 2003;62(3):6-14.
  9. Hofner K, Claes H, De Reijke TM, et al. Tamsulosin 0,4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
  10. Лопаткин Н.А., Аляев Ю.Г., Коган М.И. и др. Эффективность и безопасность применения доксазозина (кардуры) при лечении больных с доброкачественной гиперплазией предстательной железы // Урология. 2003. № 5. С. 3-4.
  11. Мазо Е.Б., Чепуров А.К. Тонокардин (доксазозин) в лечении симптомов нижних мочевых путей // Урология. 2003. № 3. С. 15-16.
  12. Chapple CR. Eur Urol 2005;4(2):33-34.
  13. Djavan B. Eur Urol 2005;4(2):61-68.
  14. Michel MC. Eur Urol 2005;4(2):53-60.
  15. Савенков М.П., Иванов С.Н., Судакова Н.И. и др. Применение альфа-адреноблокаторов при доброкачественной гиперплазии предстательной железы: есть ли повод для сотрудничества с кардиологом? // Фарматека. 2004. № 16. С. 2-8.
  16. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13.
  17. Foglar R, Shibata K, Horia K, et al. Use of recombinant 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-07.
  18. Pressel S, Davis B, Wright J. Operational aspects of terminating the doxazosin arm of the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Controlled Clin Trials 2001;22:29-41.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##